App-Quantinova.ai

Mepolizumab reduces disease symptoms for Patients with Chronic Rhinosinusitis with Nasal Polyps: Data from the SYNAPSE study

Maggie Tabberer - American Academy of Allergy, Asthma, and Immunology (AAAAI) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Mepolizumab

Evaluating sensitization patterns on ImmunoCAP-detected polysensitized patients with microarray-based multiplex assay (ISAC)

Sujoy Khan - American Academy of Allergy, Asthma, and Immunology (AAAAI) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

A Responder Analysis To Demonstrate Dupilumab Treatment Effect Across Objective and Patient-Reported Subjective Endpoints For Patients with Severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Claus Bachert - American Academy of Allergy, Asthma, and Immunology (AAAAI) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Dupilumab

Jorge Maspero - American Academy of Allergy, Asthma, and Immunology (AAAAI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Impact of mepolizumab on symptom severity in patients with hypereosinophilic syndrome

Florence Roufosse - American Academy of Allergy, Asthma, and Immunology (AAAAI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hypereosinophilic Syndrome

Mepolizumab

Impact of Baseline Blood Eosinophil Count on Flare Reduction in Mepolizumab-Treated Patients With Hypereosinophilic Syndrome

Marc Rothenberg - American Academy of Allergy, Asthma, and Immunology (AAAAI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hypereosinophilic Syndrome

Mepolizumab

Description of Hypereosinophilic syndrome (HES) and subtypes in the literature

Praveen Akuthota - American Academy of Allergy, Asthma, and Immunology (AAAAI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hypereosinophilic Syndrome

N/A

Efficacy of Lanadelumab in Hereditary Angioedema Patients With and Without Prior Use of Long-Term Prophylaxis: Final Results From the HELP Open-Label Extension Study

Kim Paes - American Academy of Allergy, Asthma, and Immunology (AAAAI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Hereditary angioedema

DX2930

Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma: Results from the Phase 3 NAVIGATOR Study

Andrew Menzies-Gow - American Academy of Allergy, Asthma, and Immunology (AAAAI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Tezepelumab

Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): Results from the CheckMate-032 study.

Dung T. Le - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastroesophageal junction (GEJ) adenocarcinoma

Nivolumab

NEOSCOPE: A randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine (OXCAP) or carboplatin/paclitaxel (CarPac) based chemoradiation (CRT) as pre-operative regimen for resectable oesophageal adenocarcinoma.

Somnath Mukherjee - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal Cancer

Capecitabine

Pathological heterogeneity after trastuzumab and combination chemotherapy in HER2+ gastroesophageal adenocarcinoma xenograft.

Connie Yip - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastroesophageal junction (GEJ) adenocarcinoma

Pimonidazole

Economic burden of advanced gastric cancer (AGC) in Taiwan.

Jihyung Hong - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

N/A

Characterizing tumor responses from RAINBOW, a randomized phase III trial of ramucirumab (RAM) plus paclitaxel (PAC) vs placebo (PBO) plus PAC in patients (pts) with previously treated advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Gyorgy Bodoky - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

Ramucirumab

Role of nutritional status as predictor of survival in oesophageal cancer treated with definitive chemoradiation (dCRT): outcome from SCOPE1, a phase II/III randomised trial of dCRT +/- cetuximab.

Samantha Cox - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal Cancer

Erbitux

Long term results and patterns of recurrence from SCOPE 1: A phase II/III randomised trial of definitive chemoradiotherapy (dCRT) plus or minus cetuximab (dCRT+C) in esophageal cancer.

Somnath Mukherjee - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal Cancer

Capecitabine

On-trial radiotherapy quality assurance in NeoSCOPE: A randomised phase II trial of chemoradiotherapy in oesophageal cancer.

Elin Evans - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal Cancer

N/A

Real world treatment patterns of previously treated advanced gastric and gastroesophageal junction adenocarcinoma (GC) in Mexico.

Kyla Jones - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastroesophageal junction (GEJ) adenocarcinoma

N/A

Phase II study of AZD4547 in FGFR amplified tumours: Gastroesophageal cancer (GC) cohort pharmacodynamic and biomarker results.

Elizabeth Catherine Smyth - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

AZD-4547

Safety, PD-L1 expression, and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced gastric or gastroesophageal junction cancer.

Hyun Cheol Chung - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastroesophageal junction (GEJ) adenocarcinoma

Avelumab

Filters

45280 Abstracts